Inclusion Criteria:
- Patients with histologically-confirmed, HR-positive (ER and/or PR), HER2-negative
metastatic breast cancer (MBC)
- Postmenopausal status defined by lack of menses for 2 years, oophorectomy, or medical
ovarian suppression
- Receiving first line endocrine-based therapy (tamoxifen, aromatase inhibitor, or
fulvestrant; concurrent molecular therapy also allowed)
- Sedentary (i.e., <60 minutes / week of exercise)
- Age >18 years
- BMI ≥ 18.5
- Cleared for exercise participation as per screening clearance via PAR-Q+
- Cleared for study participation as per screening consultation with an MSK Exercise
Physiologist
- Willingness to comply with all study-related procedures
- Patients with "treated and stable" brain lesions of a duration of ≥ 2 months may be
enrolled
Exclusion Criteria:
- Life expectancy <6 months
- Enrollment onto any other therapeutic investigational study
- Mental impairment leading to inability to cooperate
- Concurrent participation in weight loss or other exercise programs